PICOPLATIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C6H7N.2Cl.Pt.H3N
Molecular Weight	376.147
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

N.[Cl-].[Cl-].[Pt++].CC1=CC=CC=N1

InChI

InChIKey=IIMIOEBMYPRQGU-UHFFFAOYSA-L

InChI=1S/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11249584 | https://www.ncbi.nlm.nih.gov/pubmed/24163749

Picoplatin is a sterically hindered platinum (II) complex with antineoplastic properties developed for the treatment of cis-platin-resistant cancer. Picoplatin alkylates DNA, forming both inter- and intra-strand cross-linkages, resulting in inhibition of DNA replication and transcription, and the induction of apoptosis. However, in Phase III trials, picoplatin failed to meet its primary endpoint for advanced cell lung cancer. It remains in development for other cancers.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA 278 Target ID: CHEMBL2311221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24212665 \| https://www.ncbi.nlm.nih.gov/pubmed/10626362	Crosslinking Agent 81

Conditions

Condition	Modality	Highest Phase	Product
Small-cell lung cancer 41 Sources: https://clinicaltrials.gov/show/NCT00465491	Primary	Phase III 656	Unknown Approved Use Unknown
Colorectal cancer 101 Sources: https://clinicaltrials.gov/ct2/show/NCT00478946	Primary	Phase II 1132	Unknown Approved Use Unknown
Hormone refractory prostate cancer 5 Sources: https://clinicaltrials.gov/ct2/show/NCT00448734	Primary	Phase II 1132	Unknown Approved Use Unknown

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	OCT1 327 OCT3 80 OCT2 355 MRP1 107

Drug as victim

Target	Modality	Activity
OCT3 80	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/20371711/	no [IC50 3.2 uM]
MRP1 107	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/9683290/	no
OCT2 355	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/20371711/	yes [IC50 0.277 uM]
OCT1 327	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/20371711/	yes [IC50 0.44 uM]

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA0022XE	https://www.aablocks.com/goods/Goods/detail?id=AA0022XE
ABI Chem	AC1L42P3
AN PharmaTech	AN-30599
Aaron Chemicals	AR0023P6	http://www.aaronchem.com/181630-15-9
Adooq BioScience	A14108	https://www.adooq.com/picoplatin.html
BioSynth	J-011604	https://www.biosynth.com/en/products/all-products/products/J-011604.html
ChemMol	49420136	http://www.chemmol.com/chemmol/49420136.html
MolPort	MolPort-006-170-014	https://www.molport.com/shop/molecule-link/MolPort-006-170-014
NovoSeek	177358
eNovation Chemicals	Y1054892	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y1054892
iChemical	EBD36764	http://www.ichemical.com/chemicals/cas-181630-15-9

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

In a clinical trial, picoplatin was administered intravenously at a dose of 150 mg/m2 every 3 weeks.

Route of Administration: Intravenous

In Vitro Use Guide

In a growth inhibition assay, ovarian carcinoma cell lines were treated serial dilutions of picoplatin for 96 h. Among the cell lines, the drug demonstrated a mean IC50 value of 8.1 uM.

Name

Type

Language

PICOPLATIN

Official Name

English

AMD473

Code

English

NX473

Code

English

PLATINUM, AMMINEDICHLORO(2-METHYLPYRIDINE)-, (SP-4-3)-

Common Name

English

Picoplatin [WHO-DD]

Common Name

English

(SP-4-3)-Amminedichloro(2-methylpyridine)platinium

Common Name

English

PICOPLATIN [MART.]

Common Name

English

AMD-473

Code

English

PICOPLATIN [USAN]

Common Name

English

ZD-0473

Code

English

picoplatin [INN]

Common Name

English

ZD0473

Code

English

PICOPLATIN [MI]

Common Name

English

NX-473

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C1450